Literature DB >> 31714595

Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.

Rohit Gosain1, Somedeb Ball2, Navpreet Rana3, Adrienne Groman1, Elizabeth Gage-Bouchard1, Arvind Dasari4, Sarbajit Mukherjee1.   

Abstract

BACKGROUND: The incidence of neuroendocrine tumors (NETs) is rapidly rising. There are very few studies investigating the role of sociodemographic factors in NETs. This study was aimed at examining how geographic and sociodemographic characteristics shape outcomes in the NET population.
METHODS: A retrospective analysis using the Surveillance, Epidemiology, and End Results database was performed, and the NET patient population from 1973 to 2015 was studied. Univariate and multivariable analyses were performed to evaluate patients' disease-specific survival (DSS) and overall survival (OS). Geographic and sociodemographic factors, including the location of residence (urban area [UA] vs rural area [RA]), sex, race, insurance status, and marital status, were included in the analysis.
RESULTS: A total of 53,034 patients (5517 in RAs and 47,517 in UAs) were included in the analysis. The incidence of NETs was found to be rising in both RAs and UAs but more rapidly in RAs (with the highest incidence in 2006-2015: 5.93 per 100,000 in RAs vs 4.10 per 100,000 in UAs). Patients from RAs presented at advanced stages in comparison with patients from UAs (regional, 18% vs 16%; distant, 15% vs 13%; P < .01). In the multivariable model, RA patients had a trend toward poorer OS (hazard ratio, 1.05; P = .053) in comparison with UA patients. The multivariable analysis showed significantly worse DSS and OS for uninsured, single, and male patients in comparison with insured, married, and female patients, respectively.
CONCLUSIONS: This study has identified sociodemographic disparities in NET outcomes. Access to health care could be a potential contributing factor, although differences in environmental exposure, health behavior, and tumor biology could also be responsible.
© 2019 American Cancer Society.

Entities:  

Keywords:  carcinoid; disparities; incidence; neuroendocrine; neuroendocrine tumor (NET); outcomes; rural; urban

Mesh:

Year:  2019        PMID: 31714595      PMCID: PMC7870292          DOI: 10.1002/cncr.32607

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  1 in total

Review 1.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

  1 in total
  4 in total

Review 1.  Rural-Urban Disparities in Cancer Outcomes: Opportunities for Future Research.

Authors:  Smita Bhatia; Wendy Landier; Electra D Paskett; Katherine B Peters; Janette K Merrill; Jonathan Phillips; Raymond U Osarogiagbon
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

2.  Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance.

Authors:  Rui Zheng-Pywell; Amanda Fang; Ahmad AlKashash; Seifeldin Awad; Sushanth Reddy; Selwyn Vickers; Martin Heslin; Vikas Dudeja; Herbert Chen; John Bart Rose
Journal:  Pancreas       Date:  2021-03-01       Impact factor: 3.243

3.  Epidemiological Analysis and Prognosis of Conjunctival Cancer in the Past Twenty Years: A Population-Based Retrospective Study Using SEER Data.

Authors:  Yumei Diao; Xiaoqi Li; Yan Huo; Zongyuan Li; Qinghua Yang; Yifei Huang; Liqiang Wang
Journal:  Biomed Res Int       Date:  2020-07-07       Impact factor: 3.411

4.  Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Si Xie; Lei Li; Xiaotong Wang; Lequn Li
Journal:  Medicine (Baltimore)       Date:  2021-01-15       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.